Skip directly to content

Improving Disparities in Ulcerative Colitis Health Care in Post COVID-19 Era

Pfizer is now inviting applications from UK health care organisations for a Quality Improvement Grant to support “Improving Disparities in Ulcerative Colitis Health Care in Post COVID-19 Era”

 

We are particularly interested in receiving proposals that:

  • Help HCPs meet the ever-changing needs of patients during this challenging time  
  • Educate HCPs regarding effective implementation of telehealth in their practice
  • Develop, implement and/or optimise existing tools designed to facilitate remote interaction between patients and HCPs.
     

Proposals for projects covering the following areas are out of scope of this call:

  • Projects bearing the name or class of specific medicines
  • Projects designed to increase the uptake of a single therapeutic agent or intervention (projects should be aimed at improving adherence to specific guidelines or patient pathways)
  • Applications for funding of services which should be provided as standard within the NHS
  • Interventional or observational clinical studies
  • In vitro or in vivo (animal) studies
  • Non-interventional studies, such as epidemiological studies
  • Outcomes research studies where the primary focus is to understand the results of particular health care practices and interventions as well as to monitor and improve the quality of care
  • Other types of independent research on disease states, including novel diagnostic screening tools and surveys

Pfizer processes these applications through the Pfizer Global Medical Grants System which enables the review and consideration of an individual grant request submission from a health care organisation. This is intended to support an independent medical and/or scientific initiative for quality improvement and to improve patient outcomes, in an area of unmet medical need that is aligned with Pfizer’s medical and/or scientific strategies.

A Quality Improvement Grant is a type of grant that supports independent quality improvement projects for systematic and continuous actions, that lead to measurable improvements in health care services and the health status of individuals. This is aimed to improve patient outcomes in areas of unmet medical need that do not relate to a Pfizer asset but that are aligned with Pfizer’s medical and/or scientific strategies (e.g., aspects of quality such as clinical competence, outcomes and process assessment, programme evaluation, quality indicators, and quality assurance).

For all independent grants, the grant requester and the health care organisation grantee is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the initiative.

Applications for this Call will be accepted between 3rd August 2020 and 7th September 2020. Applications are anticipated to be judged by October 2020. The total amount of funding available for this Call will be £180,000. This is intended to be used to fund up to 3 successful applications. Grant applications will be reviewed by Pfizer colleagues that hold relevant medical and compliance positions within the organisation.

Grants will be awarded on a 'first come, first served basis', subject to the criteria set out in the Call for Improving Disparities in UC Care Grant Application, which also contains the full details of this call.

 

Apply for Improving Disparities in Ulcerative Colitis Health Care in Post COVID-19 Era

Note: First-time users will need to use their health care organisation / NHS email address and Create a password.

If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the log-in webpage

To contact Pfizer for any other purpose, including adverse event reports, medical information requests, or data protection enquiries please call 01304 616161

 

PP-INP-GBR-0134 / Sept 2020